Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s

Merck said on Monday it has raised its outlook for new growth drivers, forecasting $70 billion in revenue from these fresh ...
EconoTimes

Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s

Merck announced on Monday that it has significantly raised its long-term growth outlook, projecting up to $70 billion in revenue from new growth drivers by the mid-2030s. The updated forecast ...

3 Dividend Stocks to Hold for the Next 10 Years

With that as the backdrop, here's a rundown of three dividend stocks to buy with plans to only hold them for the next 10 ...

Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook

Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.
Investing.com Australia

Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked in - Wolfe

Wolfe upgraded Merck to Outperform from Peer Perform and set a $135 price target, saying the drugmaker is approaching a new ...
FiercePharma

Merck's Keytruda flunks pivotal studies in early-stage lung and skin cancers

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. Merck has ...
Pharmabiz

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...